Physician profile
Navin C Shah
NPI 1346225000
$6,079.50
in general payments reported to CMS, 2019-2025
37 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $688 · 2020: $589 · 2021: $1,032 · 2022: $1,166 · 2023: $1,005 · 2024: $795 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,604.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,604.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,040.40 | 2019-2025 | Erleada, Carvykti, Rybrevant |
| Astellas Pharma US INC | $668.38 | 2019-2025 | Xtandi, Veozah |
| Endo Pharmaceuticals INC. | $381.47 | 2019-2024 | Aveed, Xiaflex, Edex |
| Dendreon Pharmaceuticals LLC | $363.37 | 2019-2024 | Provenge |
| Pfizer INC. | $328.83 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $327.33 | 2023-2025 | Orgovyx, Gemtesa |
| Tolmar, INC. | $285.70 | 2023-2025 | Eligard, Jatenzo |
| Abbvie INC. | $281.46 | 2019-2025 | Lupron Depot, Botox |
| Bayer Healthcare Pharmaceuticals INC. | $277.86 | 2020-2025 | |
| Tolmar Pharmaceuticals, INC. | $203.56 | 2019-2022 | |
| Myovant Sciences INC. | $201.29 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $199.37 | 2021-2025 | Erleada |
| Ferring Pharmaceuticals INC. | $161.35 | 2019-2025 | Adstiladrin |
| Antares Pharma, INC. | $157.59 | 2019-2024 | Xyosted |
| Endo USA, INC. | $123.40 | 2024-2025 | Xiaflex, Aveed, Edex |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $95.14 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $88.00 | 2024-2025 | |
| Urovant Sciences INC | $87.85 | 2022 | |
| Boston Scientific Corporation | $86.50 | 2019-2022 | |
| Accord Healthcare, INC. | $83.63 | 2022-2023 | |
| Blue Earth Diagnostics | $80.93 | 2019-2023 | |
| Acerus Pharmaceuticals Corporation | $56.84 | 2020-2021 | |
| Olympus America INC. | $56.28 | 2021-2023 | Itind System |
| Allergan, INC. | $53.71 | 2019-2020 | |
| Amgen INC. | $53.02 | 2019-2021 | |
| Myriad Genetic Laboratories, INC. | $48.16 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $45.63 | 2023-2024 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $43.46 | 2023 | Keytruda, Lynparza, Welireg |
| Medtronic, INC. | $42.54 | 2022 | |
| Convatec INC. | $28.45 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $23.35 | 2020 | |
| Clarus Therapeutics INC. | $22.23 | 2021 | |
| Telix Pharmaceuticals | $19.98 | 2024 | Illuccix |
| Foundation Medicine, INC. | $17.83 | 2021 | |
| Axonics, INC. | $16.26 | 2022 | |
| Neotract INC. | $14.24 | 2019 | |
| Mission Pharmacal Company | $14.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navin Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.